Kirby McInerney LLP Advises Esperion Therapeutics, Inc. Investors of Potential Claims

The law firm of Kirby McInerney LLP announced today that a class action lawsuit has been filed in the United States District Court for the Eastern District of Michigan against Esperion Therapeutics, Inc. ("Esperion" or the "Company") (Nasdaq: ESPR) on behalf of all persons or entities who acquired Esperion securities during the period from August 18, 2015 through September 28, 2015 (the "Class Period"). Pursuant to applicable law, investors have until March 14, 2016 to file a motion to be appointed as lead plaintiff in the investor lawsuit.

The lawsuit alleges that during the Class Period, the Company falsely portrayed the events of an early August 2015 meeting with the U.S. Food and Drug Administration (“FDA”). On August 17, 2015, Esperion stated that during this meeting, the FDA had informed the Company that it would not need to complete a cardiovascular outcomes trial to gain approval of its lead product candidate, ETC-1002.

After the market closed on September 28, 2015, Esperion disclosed that the FDA had actually encouraged it to “initiate a cardiovascular outcomes trial promptly.” On this news, the stock price declined from $35.09 to close at $18.33 on September 29, 2015.

If you acquired Esperion securities during the Class Period and are interested in learning more about this matter and any rights you might have with respect to these claims, contact Rona Li at securitiescases@kmllp.com, or by telephone at (212) 371-6600. Please bear in mind that some of these rights may be time-sensitive.

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, whistleblower, antitrust and consumer litigation. The firm has specialized in complex litigation, including securities class actions, for several decades. Kirby McInerney LLP has repeatedly demonstrated its expertise in this field, and has been recognized by various courts that have appointed the firm to major positions in consolidated and multi-district litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars, and the firm's achievements and quality of service have been chronicled in numerous published decisions. Additional information about the firm or the claims against Esperion Therapeutics, Inc. can be found at Kirby McInerney LLP's website: http://www.kmllp.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160113006005/en/

Kirby McInerney LLPRona Li, (212) 371-6600securitiescases@kmllp.com

Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024